These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37168321)

  • 1. Bivalirudin Presents a Favorable Safety Profile Regarding Adverse Drug Reactions, Thrombocytopenia, and Bleeding in Chinese Patients With High Bleeding Risk Undergoing Percutaneous Coronary Intervention: A Prospective, Multi-Center, Intensive Monitoring Study.
    Peng X; Li Z; Li D; Li Z; Lu Z; Luo C; Ji Z
    Front Cardiovasc Med; 2022; 9():821322. PubMed ID: 37168321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety profile of bivalirudin in Chinese female patients undergoing percutaneous coronary intervention: a multi-center study.
    Wu F; Liu X; Ran H; Tang Q; Zhong C; Wu Y; Xiao J
    BMC Cardiovasc Disord; 2022 Feb; 22(1):58. PubMed ID: 35172721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Occurrence and Risk Factors of Adverse Drug Reactions in Patients Receiving Bivalirudin as Anticoagulant During Percutaneous Coronary Intervention: A Prospective, Multi-Center, Intensive Monitoring Study.
    Li P; Zhang H; Luo C; Ji Z; Zheng Z; Li Z; Wu F; Li J; Hong L
    Front Cardiovasc Med; 2021; 8():781632. PubMed ID: 35573935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive safety profile evaluation of bivalirudin in Chinese ST-segment elevation myocardial infarction patients receiving percutaneous coronary intervention: a prospective, multicenter, intensive monitoring study.
    Zheng H; Wang Z; Li Q; Zhao Y; Liu Y; Chen A; Deng J; Su G
    BMC Cardiovasc Disord; 2022 Jun; 22(1):290. PubMed ID: 35752771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in high-bleeding-risk patients with acute coronary syndrome in contemporary practice.
    Zhang Y; Zhang Y; Liu Z; Zhang B; Liu G; Chen K
    Biomed Pharmacother; 2020 Oct; 130():110758. PubMed ID: 34321166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficiency and safety of bivalirudin in patients undergoing emergency percutaneous coronary intervention via radial access: A subgroup analysis from the bivalirudin in acute myocardial infarction versus heparin and GPI plus heparin trial.
    Wang H; Li Y; Cong H; Ding S; Liu B; Li L; Chen Y; Jia S; Jing Q; Zhao X; Liu H; Liang Z; Li J; Bao D; Han Y
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):1157-1165. PubMed ID: 27677411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bivalirudin in percutaneous coronary intervention for chronic total occlusion: A single-center pilot study.
    Li C; Xu R; Shen Y; Dai Y; Zhang F; Ma J; Ge L; Qian J; Ge J
    Catheter Cardiovasc Interv; 2018 Mar; 91(4):679-685. PubMed ID: 28766879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial.
    Li Y; Liang Z; Qin L; Wang M; Wang X; Zhang H; Liu Y; Li Y; Jia Z; Liu L; Zhang H; Luo J; Dong S; Guo J; Zhu H; Li S; Zheng H; Liu L; Wu Y; Zhong Y; Qiu M; Han Y; Stone GW
    Lancet; 2022 Nov; 400(10366):1847-1857. PubMed ID: 36351459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of bivalirudin during percutaneous coronary intervention in high-bleeding-risk elderly patients with chronic total occlusion: A prospective randomized controlled trial.
    Wang Y; Zhao HW; Wang CF; Fan CY; Zhang XJ; Zhu Y; Luo DF; Yu GN; Hou AJ; Luan B
    Catheter Cardiovasc Interv; 2019 Feb; 93(S1):825-831. PubMed ID: 30724035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.
    Han Y; Guo J; Zheng Y; Zang H; Su X; Wang Y; Chen S; Jiang T; Yang P; Chen J; Jiang D; Jing Q; Liang Z; Liu H; Zhao X; Li J; Li Y; Xu B; Stone GW;
    JAMA; 2015 Apr; 313(13):1336-46. PubMed ID: 25775052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of unfractionated heparin or bivalirudin on patients with stable coronary artery disease undergoing percutaneous coronary intervention.
    Lima FV; Gruberg L; Aslam U; Ramgadoo M; Clase K; Trevisan A; Jeremias A
    J Interv Cardiol; 2018 Apr; 31(2):177-184. PubMed ID: 29205487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results.
    Mahaffey KW; Lewis BE; Wildermann NM; Berkowitz SD; Oliverio RM; Turco MA; Shalev Y; Ver Lee P; Traverse JH; Rodriguez AR; Ohman EM; Harrington RA; Califf RM;
    J Invasive Cardiol; 2003 Nov; 15(11):611-6. PubMed ID: 14608128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bivalirudin vs. heparin on a background of ticagrelor and aspirin in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A multicenter prospective cohort study.
    Yu XF; Chen HW; Xu J; Xu QZ; Zhang XH; Li BB; Xu BL; Ma LK
    Front Cardiovasc Med; 2022; 9():932054. PubMed ID: 36386368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study).
    Patti G; Pasceri V; D'Antonio L; D'Ambrosio A; Macrì M; Dicuonzo G; Colonna G; Montinaro A; Di Sciascio G
    Am J Cardiol; 2012 Aug; 110(4):478-84. PubMed ID: 22583760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bivalirudin in patients undergoing percutaneous coronary intervention and independent predictors of postoperative adverse events in these patients: A real world retrospective study.
    Hu YC; Yao WJ; Jin DX; Zhang JX; Wang L; Zhang R; Xu JH; Cong HL
    Medicine (Baltimore); 2021 Mar; 100(10):e25003. PubMed ID: 33725878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel approaches for preventing or limiting events (Naples) III trial: randomized comparison of bivalirudin versus unfractionated heparin in patients at increased risk of bleeding undergoing transfemoral elective coronary stenting.
    Briguori C; Visconti G; Focaccio A; Donahue M; Golia B; Selvetella L; Ricciardelli B
    JACC Cardiovasc Interv; 2015 Mar; 8(3):414-423. PubMed ID: 25703878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials.
    Stone GW; Mehran R; Goldstein P; Witzenbichler B; Van't Hof A; Guagliumi G; Hamm CW; Généreux P; Clemmensen P; Pocock SJ; Gersh BJ; Bernstein D; Deliargyris EN; Steg PG
    J Am Coll Cardiol; 2015 Jan; 65(1):27-38. PubMed ID: 25572507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention.
    Tavano D; Visconti G; D'Andrea D; Focaccio A; Golia B; Librera M; Caccavale M; Ricciarelli B; Briguori C
    Am J Cardiol; 2009 Nov; 104(9):1222-8. PubMed ID: 19840566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Bivalirudin-Associated Major Adverse Cardiac and Hemorrhagic Events in Acute Coronary Syndrome Patients on Chronic Dialysis Following Percutaneous Coronary Intervention.
    Fu D; Liu M; Gao T; Li C; Liao J; Shao M; Xiao X; Yang P; Li X; Jiang H
    J Invasive Cardiol; 2021 Nov; 33(11):E877-E883. PubMed ID: 34653957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial.
    Valgimigli M; Frigoli E; Leonardi S; Vranckx P; Rothenbühler M; Tebaldi M; Varbella F; Calabrò P; Garducci S; Rubartelli P; Briguori C; Andó G; Ferrario M; Limbruno U; Garbo R; Sganzerla P; Russo F; Nazzaro M; Lupi A; Cortese B; Ausiello A; Ierna S; Esposito G; Ferrante G; Santarelli A; Sardella G; de Cesare N; Tosi P; van 't Hof A; Omerovic E; Brugaletta S; Windecker S; Heg D; Jüni P;
    Lancet; 2018 Sep; 392(10150):835-848. PubMed ID: 30153988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.